Cabaletta Bio Inc(CABA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.58 | Insider Own | 11.59% | Shs Outstand | 167.7M | Perf Week | -1.3% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | 11.96% | Insider Trans | - | Shs Float | 149.9M | Perf Month | -23.23% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.32 | Inst Own | 83.32% | Short Float | 26.21% | Perf Quarter | -44.12% |
| Income | -0.18B | P/S | - | EPS this Y | 35.13% | Inst Trans | 64.82% | Short Ratio | 7.81 | Perf Half Y | -45.32% |
| Sales | 0.00B | P/B | 1.21 | EPS next 5Y | 22.07% | ROA | -75.36% | Short Interest | 39.29M | Perf YTD | -30.59% |
| Book/sh | 1.26 | P/C | 1.14 | EPS past 3/5Y | -5.18% -7.84% | ROE | -93.2% | 52W High | -64.07% ($4.23) | Perf Year | -44.53% |
| Cash/sh | 1.33 | P/FCF | - | Sales past 3/5Y | - | ROIC | -83.63% | 52W Low | 15.15% ($1.32) | Perf 3Y | -88.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 41.56% | Gross Margin | - | Volatility(W/M) | 8.54% 8.75% | Perf 5Y | -88.77% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.79 | EPS Q/Q | 53.72% | Profit Margin | - | RSI (14) | 36.05 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.79 | Sales Q/Q | - | SMA20 | -10.18% ($1.69) | Beta | 3.53 | Target Price | $13.25 |
| Payout | - | Debt/Eq | 0.12 | Earnings | 2026/8/13 | SMA50 | -35.78% ($2.37) | Rel Volume | 1.16 | Prev Close | $1.46 |
| Employees | 156 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 8.82% - | SMA200 | -46.89% ($2.86) | Avg Volume(3M) | 5.03M | Price | $1.52 |
| IPO | 2019/10/25 | Option/Short | Yes/Yes | Trades | 6886 | Volume | 5,831,833 | Change | 4.47% |
🧬 A US clinical-stage biotech company developing innovative cell therapies to treat B-cell-mediated autoimmune diseases. Headquartered in the US, the company is conducting clinical trials to develop its lead pipeline candidate, a CD19-targeting CAR-T cell therapy (rese-cel), as a treatment for various autoimmune diseases, including systemic lupus erythematosus, myositis, and systemic sclerosis.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded about as much as usual. That is 116% of its average volume.
CABA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +35.1% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #281 of 594 in the industry
Based on market cap of $258M.
FAQ
What kind of company is CABA?
CABA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CABA?
The market cap of CABA is approximately $258M, ranking 3,815 within its sector.
What is the 52-week high and low for CABA?
CABA has recorded a 52-week high of $4.23 and a low of $1.32.
